Alzheimer Disease Clinical Trials

135 studies are recruiting for alzheimer disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Dementia Care Partner Hospital Assessment Tool

   The purpose of this study is to see whether an adapted questionnaire called the Care Partner Hospital Assessment Tool (CHAT) for care partners of hospitalized patients living with Alzheimer's disease and related dementias (ADRD) (CHAT-AD) can help people with dementia receive better care after they…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Wisconsin, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT05592366 on ClinicalTrials.gov

2. Using the EHR to Advance Genomic Medicine Across a Diverse Health System

   Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Penn Medicine, Philadelphia, Pennsylvania

   Run by

   University of Pennsylvania

   See if you can join NCT06377033 on ClinicalTrials.gov

3. UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

   The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, br…

   Stage

   Phase 2

   Ages

   50 and older

   Site

   University of Alabama at Birmingham Medical Center, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT03503331 on ClinicalTrials.gov

4. UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy

   The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, g…

   Stage

   Phase 1

   Ages

   50 and older

   Site

   UAB, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT03809351 on ClinicalTrials.gov

5. Early Age-Related Hearing Loss Investigation (EARHLI)

   Early Age-Related Hearing Loss Investigation (EARHLI) is a single site study that will randomize late middle age adults to either a hearing intervention (including hearing aids) or a health education intervention. Participants will be followed for 1 year. This study will provide information on redu…

   Stage

   Not phased

   Ages

   55 to 75

   Site

   Columbia University Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT06174038 on ClinicalTrials.gov

6. Autoimmune Features of Neurodegenerative Disorders

   This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD). The investigators plan to recruit 30 PD, 30 AD/Amnestic Mild Cognitive Impairment (aMCI), and 60 age matched healthy controls in this study to study the role of immu…

   Stage

   Not phased

   Ages

   55 to 90

   Site

   Columbia University Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT04239079 on ClinicalTrials.gov

7. Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

   This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.

   Stage

   Not phased

   Ages

   21 to 80

   Site

   Mayo Clinic, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT02740634 on ClinicalTrials.gov

8. Improving Access to Care for Veterans With Memory Loss

   This study evaluates a care delivery protocol to improve access to care for Veterans with Alzheimer's Disease and Related Disorders (ADRD). A randomized controlled trial will enroll Veterans with mild cognitive impairment or early dementia at VA Pittsburgh. The ADRD care delivery protocol integrate…

   Stage

   Not phased

   Ages

   18 and older

   Site

   VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania

   Run by

   VA Pittsburgh Healthcare System

   See if you can join NCT07117162 on ClinicalTrials.gov

9. A Feasiblity Study of Green Activity Program for People Living With Memory Challenges

   The purpose of this study is to test the Green Activity Program that was designed with people living with memory challenges and their study partners to see if it can be done and if they enjoy the program. "Green activities" are nature activities that the person enjoys and can be done with other peo…

   Stage

   Not phased

   Ages

   45 and older

   Site

   Indiana University Bloomington, Bloomington, Indiana

   Run by

   Indiana University

   See if you can join NCT06403345 on ClinicalTrials.gov

10. Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease

    The project is a placebo-controlled study that aims to use closed-loop transcranial alternating current stimulation (tACS) to study patients with symptoms of mild cognitive impairment which is likely due to Alzheimer's disease or another form of dementia (AD-MCI). Patients will undergo an EEG and c…

    Stage

    Not phased

    Ages

    50 to 80

    Site

    Massachusetts General Hospital, Charlestown, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05904132 on ClinicalTrials.gov

11. Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)

    CORT-X will examine if mitigation of stress-mediated pathogenesis of Alzheimer's disease (AD) is a feasible target for intervention in individuals at risk for this disease. This single-site (Baltimore, Maryland) phase II clinical trial is a 2-week, randomized, placebo-controlled crossover study of …

    Stage

    Phase 2

    Ages

    55 and older

    Site

    Johns Hopkins School of Medicine, Baltimore, Maryland

    Run by

    Johns Hopkins University

    See if you can join NCT04601038 on ClinicalTrials.gov

12. Sleep Trial to Prevent Alzheimer's Disease

    The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.

    Stage

    Phase 2

    Ages

    65 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    University of Minnesota

    See if you can join NCT04629547 on ClinicalTrials.gov

13. DORA and LP in Alzheimer's Disease Biomarkers

    The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.

    Stage

    Phase 2

    Ages

    65 and older

    Site

    Washington University in St. Louis, School of Medicine, St Louis, Missouri

    Run by

    University of Minnesota

    See if you can join NCT06274528 on ClinicalTrials.gov

14. Epidemiology and Biomarker Study in Alzheimer's Disease

    Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

    Stage

    Phase 3

    Ages

    55 to 75

    Site

    Care Access - Houston, Houston, Texas

    Locations

    4 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07142954 on ClinicalTrials.gov

15. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

    Stage

    Phase 3

    Ages

    55 and older

    Site

    Care Access - Huntington Beach, Huntington Beach, California

    Locations

    59 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07602582 on ClinicalTrials.gov

16. Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

    The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). F…

    Stage

    Phase 2

    Ages

    50 and older

    Site

    Columbia University Irving Medical Center, New York, New York

    Run by

    Columbia University

    See if you can join NCT04576793 on ClinicalTrials.gov

17. A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

    The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.

    Stage

    Phase 3

    Ages

    55 to 90

    Site

    Gilbert Neurology Partners/CCT Research, Gilbert, Arizona

    Locations

    22 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06947941 on ClinicalTrials.gov

18. Neurologic Stem Cell Treatment Study

    This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain n…

    Stage

    Not phased

    Ages

    18 and older

    Site

    MD Stem Cells, Westport, Connecticut

    Locations

    3 in total

    Run by

    MD Stem Cells

    See if you can join NCT02795052 on ClinicalTrials.gov

19. Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition

    Progressive age-related cognitive deficits occurring in both AD and DS have been connected to the degeneration of several neuronal populations, but mechanisms are not fully elucidated. The most consistent neuronal losses throughout the progression of AD are seen in cholinergic neurons where these l…

    Stage

    Phase 2

    Ages

    18 to 55

    Site

    Vanderbilt University Medical Center Clinical Research Center, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT05231798 on ClinicalTrials.gov

20. Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease

    Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. The Tsai lab found th…

    Stage

    Not phased

    Ages

    55 to 90

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT05776641 on ClinicalTrials.gov

21. Olfactory Biopsies

    This research study aims to investigate the function of the olfactory lining in the nasal cavity and its potential alterations in both healthy and diseased conditions. The olfactory lining is involved in the sense of smell. The purpose of this study is to collect tissue from the nasal cavity.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Duke University Health Center, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT07021040 on ClinicalTrials.gov

22. Music for Pain and Dementia

    This study aims to provide mechanistic insights into how group drumming as a music-based intervention (MBI) affects pain responses and nociceptive function in individuals with Alzheimer's Disease (AD), mild dementia or mild cognitive impairment (MCI). Heart rate (HR), heart rate variability (HRV), …

    Stage

    Not phased

    Ages

    50 to 80

    Site

    Connecticut Mental Health Clinic, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT07602283 on ClinicalTrials.gov

23. Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

    Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant nee…

    Stage

    Not phased

    Ages

    40 and older

    Site

    University of Texas at Austin, Austin, Texas

    Locations

    3 in total

    Run by

    Stephanie Grasso

    See if you can join NCT05741853 on ClinicalTrials.gov

24. Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia

    The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoed…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    University of Texas at Austin, Austin, Texas

    Run by

    University of Texas at Austin

    See if you can join NCT06511752 on ClinicalTrials.gov

25. Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1

    This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called [11C]-CS1P1 to identify inflammation in the brain by testing with healthy older adults and with cognitively impaired older adults.

    Stage

    Not phased

    Ages

    50 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT06129838 on ClinicalTrials.gov